Head-to-head
MEDVi vs Direct Meds
Compared on both medications across the eight dimensions this database records. They differ on 4 of those eight. MEDVi is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
MEDVi is $399 a month all-in for tirzepatide; Direct Meds is $399. Over twelve months that is $4,788 against $4,788. Value Scores are 57.4 and 45.1 out of 100.
Tirzepatide
Plan pages: MEDVi plans · Direct Meds plans
At 10 mg/week, MEDVi is $399 a month all-in and Direct Meds is $399, identical figures. Over twelve months the totals are $4,788 (billed monthly) and $4,788 (billed monthly).
MEDVi charges a flat $399 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
Direct Meds prices tirzepatide by dose: $299 per month at 2.5 mg rising to $399 at 10 mg, a difference of $100 a month between the bottom and top of the ladder. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.
| Dose | MEDVi | Rank | Direct Meds | Rank | Cheaper |
|---|---|---|---|---|---|
| 2.5 mg | $399 | 27/31 | $299 | 17/31 | Direct Meds by $100 |
| 5 mg | $399 | 15/17 | — | — | only MEDVi publishes |
| 7.5 mg | $399 | 14/17 | — | — | only MEDVi publishes |
| 10 mg | $399 | 21/27 | $399 | 20/27 | level |
| 12.5 mg | $399 | 14/17 | — | — | only MEDVi publishes |
| 15 mg | $399 | 14/17 | — | — | only MEDVi publishes |
The lead changes with the dose. Between 2.5 mg and 10 mg it passes to MEDVi. Pick on the dose you expect to settle at, not the headline.
Across the 27 programs this database can rank on tirzepatide, MEDVi sits 21 of 27 on all-in monthly cost and Direct Meds sits 22. They are adjacent in the field, with nothing priced between them. The field median is $339 and the floor is $169, so both sit above the median. MEDVi is $230 above the cheapest tirzepatide program on record. Direct Meds is $230 above the cheapest tirzepatide program on record.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — MEDVi undercuts it by $50, Direct Meds by $50. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | MEDVi | Direct Meds | Cheaper |
|---|---|---|---|
| Month to month | $399 | $399 | level |
| Settled dose | MEDVi | Direct Meds | Difference |
|---|---|---|---|
| 2.5 mg | $4,788 | $3,588 | $1,200 apart |
| 5 mg | $4,788 | — | one side unpriced |
| 7.5 mg | $4,788 | — | one side unpriced |
| 10 mg | $4,788 | $4,788 | $0 apart |
| 12.5 mg | $4,788 | — | one side unpriced |
| 15 mg | $4,788 | — | one side unpriced |
MEDVi publishes no rate for 3-month term, 6-month term, 12-month term; Direct Meds publishes none for 3-month term, 6-month term, 12-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $4,788 on MEDVi and $4,688 on Direct Meds — $100 apart, and a different gap from the $0 you would get by multiplying the monthly difference by twelve. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
That calculation is partial: Direct Meds publishes no price at 2 of them, so the maintenance rate stands in for the missing steps rather than a number the company has stated.
Value Scores are 57.4 for MEDVi and 45.1 for Direct Meds, against a tirzepatide category floor of $169. MEDVi leads by 12.3 points, and the margin comes from structure rather than price alone.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| MEDVi | 29.6 | 12.8 | 10 | 5 | 57.4 |
| Direct Meds | 29.6 | 10.5 | 0 | 5 | 45.1 |
Semaglutide
Plan pages: MEDVi plans · Direct Meds plans
At 2.4 mg/week, MEDVi is $299 a month all-in and Direct Meds is $297 — $2 apart, or $24 across a year. Over twelve months the totals are $3,588 (billed monthly) and $3,564 (billed monthly).
MEDVi charges a flat $299 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
Direct Meds prices semaglutide by dose: $249 per month at 0.25 mg rising to $297 at 2.4 mg, a difference of $48 a month between the bottom and top of the ladder. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
Direct Meds is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Value Scores are 58.0 for MEDVi and 45.9 for Direct Meds, against a semaglutide category floor of $129. MEDVi leads by 12.1 points, and the margin comes from structure rather than price alone.
Where the two programs differ
Cancellation terms
Cancellation differs: MEDVi states Cancel before renewal, while Direct Meds states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
MEDVi asks for Month-to-month; Direct Meds asks for Monthly (no commitment indicated). This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Dose policy
MEDVi charges one price at every dose; Direct Meds prices by dose. That difference usually matters more than the headline gap, because the tiered program's advertised figure describes the dose you start on, not the dose you settle at.
Evidence status
The two prices are not equally well evidenced. MEDVi's figure is provider-stated and Direct Meds's is reported. MEDVi rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.
All-in monthly
Both programs land at the same all-in monthly figure of $399, so price alone does not separate them and the decision moves to structure.
Membership fee
Neither charges a separate membership fee.
Shipping
Shipping is handled the same way by both — included in the quoted price.
Twelve-month cost
Over twelve months the totals are $4,788 for MEDVi and $4,788 for Direct Meds. Direct Meds is lower by $0 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
What each record says
MEDVi Official site
MEDVi advertises a $179 semaglutide start that tiers to $299 at maintenance; tirzepatide is $399 flat.
It does not publicly name its compounding pharmacy; the record shows Partner pharmacies, so who actually makes the medication cannot be independently verified; commitment terms are Month-to-month; cancellation is Cancel before renewal; availability is stated as Most US states.
Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — medvi.com pricing capture 2026-08-05
Watch: Start-vs-maintenance spread on semaglutide; compare on maintenance.
Direct Meds Official site
Direct Meds offers compounded GLP-1s in multiple formats — sublingual and injectable — with all-inclusive pricing verified on its own product pages. Semaglutide runs $249–$297/mo and tirzepatide $299–$399/mo depending on format; the lower figures are for sublingual delivery.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly named), so who actually makes the medication cannot be independently verified; commitment terms are Monthly (no commitment indicated); cancellation is Per provider terms; availability is stated as Confirm at intake.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, Direct Meds product pages verified 2026-07-25
Watch: Pricing varies by format and page; product-page 'all-inclusive' rates differ from homepage promo cards. Rank is based on injectable rate as primary. Reported status — RangeYourself verified 2026-07-25 on Direct Meds' own product pages.
What neither record tells you
MEDVi does not publish
- no published twelve-month tirzepatide rate
- no published twelve-month semaglutide rate
- no named compounding pharmacy
- no state-by-state availability list — it says Most US states
Direct Meds does not publish
- no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
- no published twelve-month tirzepatide rate
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no published twelve-month semaglutide rate
- no named compounding pharmacy
- no state-by-state availability list — it says Confirm at intake
- no specific cancellation or refund terms
Ask MEDVi and Direct Meds for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. Direct Meds carries a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Which one suits which reader
On the lowest standing monthly rate for tirzepatide, MEDVi Official site wins this matchup. If you expect to titrate to the top of the ladder, medvi's flat pricing is worth more than the headline gap suggests; and if you would rather trust a better-evidenced number, medvi's price rests on stronger provenance.
Both figures should be checked at the provider's own checkout before you pay. MEDVi's tirzepatide price is provider-stated as of 2026-08-05; Direct Meds's is reported as of 2026-07-25.
Questions
Is MEDVi or Direct Meds cheaper for tirzepatide?
MEDVi is cheaper on all-in monthly cost at 10 mg/week: $399 against $399, a difference of $0 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of MEDVi versus Direct Meds?
MEDVi works out to $4,788 across twelve months and Direct Meds to $4,788, on the plan terms each publishes.
Does MEDVi or Direct Meds raise the price as the dose goes up?
MEDVi: no, it charges one flat rate at every dose. Direct Meds: yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do MEDVi and Direct Meds differ?
4 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of MEDVi and Direct Meds names its pharmacy?
Neither. MEDVi records Partner pharmacies and Direct Meds records Partner 503A pharmacy (not publicly named). Without a named pharmacy, neither program's licensing or inspection history can be checked before you order.
How well evidenced are the MEDVi and Direct Meds prices?
MEDVi's tirzepatide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-08-05. Direct Meds's is reported, captured 2026-07-25. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Which is cheaper for semaglutide?
Direct Meds, at $297 a month all-in against $299 at 2.4 mg/week. The two programs do not necessarily lead on both medications.
Official sources: MEDVi official site · Direct Meds official site. Compounded tirzepatide and semaglutide are not FDA-approved products.